Exciting New Findings from Altimmune at EASL Congress
Altimmune, Inc. (Nasdaq: ALT), a biopharmaceutical company specializing in innovative peptide-based therapies, recently unveiled remarkable analyses during the European Association for the Study of the Liver (EASL) Congress in Amsterdam. These insights primarily focus on the efficacy of pemvidutide, a dual receptor agonist designed to tackle metabolic dysfunction-associated steatotic liver disease (MASLD).
The MASH Resolution Index: A Game Changer
At the heart of the presentation lies the MASH Resolution Index (MASHResInd), a groundbreaking algorithm developed by esteemed Dr. Rohit Loomba. This score amalgamates various non-invasive tests, such as MRI proton-density fat fraction, and liver enzyme levels to predict MASH resolution. The algorithm's application to previous clinical trial data reveals an impressive probability of MASH resolution for patients treated with pemvidutide.
Significant Results Speak Volumes
Dr. Loomba articulated, "These findings highlight pemvidutide's potential to drive significant histological improvements in MASH via non-invasive markers. The promising results from the MASHResInd model suggest a high likelihood of MASH resolution, particularly in the IMPACT Phase 2b trial of pemvidutide." The analyses indicated that among subjects receiving varying doses of pemvidutide, an astounding 69.2% to 90.9% responded positively, compared to just 22.2% in the placebo group.
IMPACT Trial and Future Directions
Dr. Scott Harris, Chief Medical Officer of Altimmune, expressed enthusiasm regarding the upcoming IMPACT trial readout, which is expected soon. He emphasized that the company's MASLD study demonstrated unprecedented reductions in liver fat — a key factor in achieving MASH resolution. With MASHResInd response rates surpassing 90% at higher doses of pemvidutide, confidence within Altimmune continues to grow.
Key Presentation Details
The poster presentation titled, "MASH resolution index: a novel, highly sensitive non-invasive measure of histologic improvement, predicts high rates of MASH resolution with pemvidutide treatment of MASH," was delivered by Dr. Shaheen Tomah, the Director of Clinical Development at Altimmune.
Clinical Progress and Ongoing Trials
Pemvidutide is not just a singular focus for Altimmune. It is also being evaluated for obesity, alcohol use disorder and alcohol liver disease. The dual agonist works by combining GLP-1 receptor suppression of appetite with glucagon’s ability to increase energy expenditure, showcasing its multifaceted potential in treating various metabolic disorders.
Company Overview and Commitment to Innovation
Altimmune’s overarching mission revolves around the development of next-generation peptide therapies aimed at significant health issues. With its innovative approach to treatments, the company stands at the forefront of addressing obesity and liver-related conditions. Currently, pemvidutide has gained Fast Track designation from the U.S. FDA for MASH treatment, and it has recently wrapped up the MOMENTUM Phase 2 trial.
Frequently Asked Questions
What is pemvidutide?
Pemvidutide is a dual receptor agonist that targets GLP-1 and glucagon receptors, being developed to treat conditions such as obesity and MASH.
What were the major findings presented at EASL?
Altimmune revealed analyses indicating high rates of MASH resolution in patients treated with pemvidutide, showing significantly better outcomes compared to the placebo group.
Who is Dr. Rohit Loomba?
Dr. Loomba is a recognized expert in hepatology, serving as a Professor of Medicine and Director of Hepatology at the University of California San Diego.
What future trials are planned for pemvidutide?
Altimmune is set to commence Phase 2 trials for Alcohol Use Disorder and Alcohol Liver Disease, following the promising results for MASH and obesity treatments.
How can I learn more about Altimmune?
For the latest information and updates, visit Altimmune’s official website.
